Literature DB >> 8111046

Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones.

D van der Harst1, E Goulmy, J H Falkenburg, Y M Kooij-Winkelaar, S A van Luxemburg-Heijs, H M Goselink, A Brand.   

Abstract

Clinical studies indicated an enhanced antileukemic effect of allogeneic bone marrow transplantation (BMT), as compared with autologous BMT. After allogeneic HLA-identical BMT, donor-derived cytotoxic T lymphocytes (CTLs) directed at minor histocompatibility (mH) antigens on the recipients, tissues can be shown. To evaluate the antileukemic reactivity of mH antigen-specific CTLs, we analyzed the expression of mH antigens on circulating lymphocytic and myeloid leukemic cells. We show that the defined mH specificities HA-1 through HA-5 and H-Y are present on leukemic cells, indicating that mH antigen-specific CTLs are capable of HLA class I-restricted antigen-specific lysis of leukemic cells. Compared with interleukin-2-stimulated normal lymphocytes, leukemic cells of lymphocytic origin are less susceptible to T-cell-mediated cytotoxicity by the HA-2 mH antigen-specific CTL and the anti-HLA-A2 CTL clone. A possible explanation for this phenomenon is impaired expression of the LFA-1 adhesion molecule. Our study suggests that mH antigen-specific HLA class I-restricted CD8+ CTLs may be involved in the graft-versus-leukemia reactivity after allogeneic BMT.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8111046

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  Expanding the immunotherapeutic potential of minor histocompatibility antigens.

Authors:  Eric Spierings; Els Goulmy
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

Review 2.  Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.

Authors:  Marie Bleakley; Cameron J Turtle; Stanley R Riddell
Journal:  Expert Rev Hematol       Date:  2012-08       Impact factor: 2.929

3.  Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia.

Authors:  W Nicholas Haining; Donna S Neuberg; Heather L Keczkemethy; John W Evans; Stephen Rivoli; Rebecca Gelman; Howard M Rosenblatt; William T Shearer; Javier Guenaga; Daniel C Douek; Lewis B Silverman; Stephen E Sallan; Eva C Guinan; Lee M Nadler
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

4.  An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells.

Authors:  Anna Sergeeva; Gheath Alatrash; Hong He; Kathryn Ruisaard; Sijie Lu; James Wygant; Bradley W McIntyre; Qing Ma; Dan Li; Lisa St John; Karen Clise-Dwyer; Jeffrey J Molldrem
Journal:  Blood       Date:  2011-02-04       Impact factor: 22.113

5.  Immunodominant minor histocompatibility antigens expressed by mouse leukemic cells can serve as effective targets for T cell immunotherapy.

Authors:  S Pion; P Fontaine; C Baron; M Gyger; C Perreault
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

6.  Analysis of cytokine production and V beta T-cell receptor subsets in irradiated recipients receiving portal or peripheral venous reconstitution with allogeneic bone marrow cells, with or without additional anti-cytokine monoclonal antibodies.

Authors:  R M Gorczynski; Z Chen; H Zeng; L Gorczynski; E Terzioglu
Journal:  Immunology       Date:  1998-02       Impact factor: 7.397

7.  Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells.

Authors:  Yi Zeng; Michael W Graner; Sylvia Thompson; Marilyn Marron; Emmanuel Katsanis
Journal:  Blood       Date:  2004-09-16       Impact factor: 22.113

Review 8.  Targeting alloreactive donor T-cells to hematopoietic system-restricted minor histocompatibility antigens to dissect graft-versus-leukemia effects from graft-versus-host disease after allogeneic stem cell transplantation.

Authors:  Tuna Mutis
Journal:  Int J Hematol       Date:  2003-10       Impact factor: 2.490

Review 9.  The role of the immune system in anti-tumour responses. Potential for drug therapy.

Authors:  S Dermime; J Barrett; C Gambacorti-Passerini
Journal:  Drugs Aging       Date:  1995-10       Impact factor: 3.923

10.  Antigens shared by malignant plasma cells and normal B cells may be involved in graft versus myeloma.

Authors:  P A Holloway; N Kaldenhoven; H M Kok-Schoemaker; B Van Kessel; W T M Van Blokland; A C Bloem; H M Lokhorst
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.